The purpose of this study is to determine the safety and tolerability of BMS-708163 in patients with Prodromal Alzheimer's disease over a treatment period of a minimum of 104-weeks. In addition patients will be seen for safety visits at 4 and 12 weeks post treatment.

Inclusion Criteria:

• Patient meets clinical criteria for prodromal Alzheimer's disease (MMSE 24-30)
• Memory complaint by subject or study partner
• CSF aβ42 levels < 200pg/mL or Total Tau/aβ42 ratio of ≥ 0.39
• Score of ≤4 on the Modified Hachinski Ischemia Scale
• CT results consistent with Alzheimer's disease
• Medically stable
• 6 years education
• Reliable study partner
• Must be able to swallow capsules

Exclusion Criteria:

• Premenopausal women
• DSM-IV diagnosis of Dementia History of stroke
• Immunocompromised
• Active peptic ulcer, GI bleed, chronic inflammatory bowel disease, chronic diarrhea or past GI surgery that would impact drug absorption
• Unstable Vitamin B-12 deficiency
• Hematologic or solid malignancy within 5 years
• Geriatric Depression Scale ≥ 6
• Unstable medical condition
• Alcohol or drug abuse history with 12-months of study entry
• Significant drug allergy
• Prisoners, compulsory psychiatric patients, or residents of nursing home or skilled nursing facility at entry
• Any other experimental therapy with 30-days of study entry